共 142 条
[1]
Farkona S(2016)Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14 73-580
[2]
Diamandis EP(2019)Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 16 563-168
[3]
Blasutig IM(2018)Immune-Related Adverse Events Associated with Immune Checkpoint Blockade N Engl J Med 378 158-1078
[4]
Martins F(2018)Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects Retina 38 1063-294
[5]
Sofiya L(2016)Ocular and orbital side-effects of checkpoint inhibitors: a review article Curr Opin Oncol 28 288-394
[6]
Sykiotis GP(2017)Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review Expert Rev Anticancer Ther 17 387-2502
[7]
Postow MA(2021)Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma Cancer Immunol Immunother 70 2497-263
[8]
Sidlow R(2021)Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone Doc Ophthalmol 142 257-318
[9]
Hellmann MD(2021)Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm Ther Adv Med Oncol 13 1758835921992989-1672
[10]
Dalvin LA(2020)A case of melanoma-associated retinopathy with autoantibodies against TRPM1 Doc Ophthalmol 141 313-518